Cardiovascular Effects of Norepinephrine

Septic Shock Clinical Trial

Official title:

Cardiac Effects of Norepinephrine After the Initial Phase of Septic Shock

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05761522
• Other study ID #: PZ23020*
• Status: Recruiting
• Start date: April 21, 2023
• Est. completion date: June 21, 2024

Study information

• Verified date: November 2023
• Source: CHU de Reims
• Contact: Olfa Hamzaoui
• Phone: 3 10 73 69 73
• Email: ohamzaoui[@]chu-reims.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Previous studies of our team reported the improvement of myocardial contractility both on hemodynamic parameters (by transpulmonary thermodilution) and morphological (by transthoracic echocardiography: TTE), during the early phase of septic shock (during the first 4 hours management of septic shock).

However, one can wonder about the effect of NAD on myocardial cardiac ouput and contractility beyond the early phase of septic shock, more precisely beyond the first 24 hours. Indeed, while it continues to act on the "stressed" blood volume and the diastolic left ventricular perfusion by increasing the diastolic arterial pressure (DAP), it has been reported in old studies that beyond the early phase, the sensitivity of the β1-adrenergic receptors is altered due to the phenomenon of internalization of these receptors, leading to a reduction of the myocardial response to catecholamines.

The investigators can then wonder whether norepinephrine still exerts a positive effect on myocardial contractility via the increase in DAP, despite an alteration of the β1-adrenergic pathway.

To answer this question, the investigators proposed to evaluate the effects of norepinephrine by TTE on cardiac contractility after the initial phase.

Description:

Patients presenting with septic shock for 24 hours or more and meeting the inclusion criteria may be included.

The course of the study will be as follows:

T0: collection (as part of usual care) of clinical circulatory parameters (heart rate, systolic/diastolic/mean blood pressure) and biological parameters (arterial lactate and ScVo2) and performance of echocardiography.

Parameters collected during TTE:

• Concerning the main judgment criterion and the secondary judgment criteria:

• Left ventricular ejection fraction (LVEF) by the Simpson Biplane method,

• Cardiac output and cardiac index by continuity equation (measurement of left ventricular outflow chamber (mm) and sub-aortic time-velocity integral (cm/s)).

• Tricuspid Annular Systolic Excursion (TAPSE) (mm)

• S wave at the tricuspid ring (cm/s)

• Other parameters collected systematically:

• Surface of the left ventricle (end-systolic and end-diastolic),

• Global strain of the left ventricle

• Mitral Annular Plane Systolic Excursion (MAPSE) (mm)

• Left ventricular filling pressure (LVRP) (at the mitral annulus, E, A, e', S' waves, E/A ratio, E/e');

• Maximum tricuspid regurgitation velocity (m/s) to estimate systolic pulmonary arterial pressure (PAPs) (mmHg)

T1: After the clinician in charge introduces or increases norepinephrine to achieve MAP ≥ 65mmHg, T1 will be when the goal of MAP ≥ 65mmHg is reached. This will be the target MAP for the management of septic shock of the patient in question according to the recommendations of learned societies.

Collection of clinical and biological circulatory parameters and performance of the TTE. The parameters collected will be the same as at T0.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 49
• Est. completion date: June 21, 2024
• Est. primary completion date: May 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adult patients >18 years old

• Septic shock after 24 hours from its diagnosis

• MAP<65 mmHg for which the physician in charge decided to increase NE

Exclusion Criteria:

• Patient under Dobutamine

• Pregnancy

• Do not resuscitation decision

Related Conditions & MeSH terms

• Septic Shock
• Shock
• Shock, Septic

Intervention

Other:
• transthoracic echocardiography
Concerning the main judgment criterion and the secondary judgment criteria: Left ventricular ejection fraction (LVEF) by the Simpson Biplane method, Cardiac output and cardiac index by continuity equation (measurement of left ventricular outflow chamber (mm) and sub-aortic time-velocity integral (cm/s)). Tricuspid Annular Systolic Excursion (TAPSE) (mm) S wave at the tricuspid ring (cm/s) Other parameters collected systematically: Surface of the left ventricle (end-systolic and end-diastolic), Global strain of the left ventricle Mitral Annular Plane Systolic Excursion (MAPSE) (mm) Left ventricular filling pressure (LVRP) (at the mitral annulus, E, A, e', S' waves, E/A ratio, E/e'); Maximum tricuspid regurgitation velocity (m/s) to estimate systolic pulmonary arterial pressure (PAPs) (mmHg)

Locations

Country	Name	City	State
France	Chu Reims	Reims

Sponsors (1)

Lead Sponsor	Collaborator
CHU de Reims

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The effect of the increase of Norepinephrine dose after restoring MAP on cardiac contractility evaluated by TTE : the left ventricular ejection fraction		through study completion, an average of 30 minutes